PRZOOM - /newswire/ -
Pleasanton, CA, United States, 2019/03/27 - Veeva Vault CDMS to manage clinical data for phase 2 and phase 3 post-operative pain trials - Vivozon.com / Veeva.com. NYSE: VEEV
Veeva Systems today announced that Vivozon, an innovative pharmaceutical company developing small molecule treatments for patients with central nervous system conditions, has selected Veeva Vault CDMS to provide electronic data capture (EDC), coding, and data cleaning for their upcoming studies of VVZ-149 to treat postoperative pain.
Vivozon is focused on developing a new mechanism-based non-narcotic and non-NSAID analgesic for patients suffering from operations, neuropathic pain, cancer pain, and more. The studies will be multicenter, randomized, double-blind, parallel group, placebo-controlled trials to evaluate the efficacy and safety of VVZ-149 injections for the treatment of post-operative pain following bunionectomy (phase 2) and abdominoplasty (phase 3).
Veeva is proud to support innovative companies like Vivozon with Veeva Vault CDMS (veeva.com/CDMS), a unified data management solution for today’s clinical trials.
Vivozon, Inc. (vivozon.com) is specialized in the discovery, development and commercialization of small molecule drugs for the treatment of patients with unmet CNS medical needs by applying an innovative approach to rapidly identify lead compounds using its unique ex vivo/phenotypic screening technology. The company is focused on the development of a safe non-opioid-next-generation pain killer for patients suffering from operations, neuropathic pain, cancer pain, and more.
About Veeva Systems
Veeva Systems, Inc. (veeva.com) is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 700 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America.